Structure Therapeutics's three largest insider shareholders as of September 29, 2026 are Ltd Fil (Other, 6.47Mn shares), Llc Fmr (Other, 5.82Mn shares), Ramy Farid (Director, 3.26Mn shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Ltd Fil | Other | 0 | 6,473,761 | 6,473,761 | 33.0% | 09 Feb, 2023 |
| 2 | Llc Fmr | Other | 0 | 5,816,554 | 5,816,554 | 29.7% | 09 Feb, 2023 |
| 3 | Ramy Farid | Director | 0 | 3,260,495 | 3,260,495 | 16.6% | 09 Feb, 2023 |
| 4 | Jun Yoon | Chief Financial Officer | 1,401,656 | 0 | 1,401,656 | 7.1% | 22 Mar, 2026 |
| 5 | Raymond C Stevens | Chief Executive Officer | 1,401,593 | 0 | 1,401,593 | 7.1% | 22 Mar, 2026 |
| 6 | Crespo Blas Coll | Chief Medical Officer | 258,228 | 0 | 258,228 | 1.3% | 22 Sep, 2026 |
| 7 | Xichen Lin | Chief Scientific Officer | 228,960 | 0 | 228,960 | 1.2% | 02 Sep, 2026 |
| 8 | Matthew Lang | Coo Gc | 184,614 | 0 | 184,614 | 0.9% | 22 Apr, 2026 |
| 9 | Ashley Hall | Chief Development Officer | 155,187 | 0 | 155,187 | 0.8% | 22 Mar, 2026 |
| 10 | John Joseph Berrios | Chief Commercial Officer | 140,766 | 0 | 140,766 | 0.7% | 07 Aug, 2026 |
| 11 | Yingli Ma | Chief Technology Officer | 139,917 | 0 | 139,917 | 0.7% | 22 Mar, 2026 |
| 12 | Daniel G Welch | Director | 0 | 123,508 | 123,508 | 0.6% | 09 Feb, 2023 |
| 13 | Mark Allen Bach | Chief Medical Officer | 26,235 | 0 | 26,235 | 0.1% | 19 Mar, 2024 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 18 Sep, 2026 | Crespo Blas Coll | Chief Medical Officer | Disposed F | 10,626 | $11.67 | $124.01K | 270,252 | Direct |
| 21 Sep, 2026 | Crespo Blas Coll | Chief Medical Officer | Disposed C | 12,024 | $0.00 | $0 | 258,228 | Direct |
| 21 Sep, 2026 | Crespo Blas Coll | Chief Medical Officer | Acquired C | 4,008 | $0.00 | $0 | 5,165 | Direct |
| 21 Sep, 2026 | Crespo Blas Coll | Chief Medical Officer | Disposed S | 4,008 | $36.15 | $144.87K | 1,157 | Direct |
| 01 Sep, 2026 | Xichen Lin | Chief Scientific Officer | Acquired M | 17,817 | $0.34 | $6.06K | 246,777 | Direct |
| 01 Sep, 2026 | Xichen Lin | Chief Scientific Officer | Disposed C | 17,817 | $0.00 | $0 | 228,960 | Direct |
| 01 Sep, 2026 | Xichen Lin | Chief Scientific Officer | Disposed M | 17,817 | $0.00 | $0 | 125,081 | Direct |
| 01 Sep, 2026 | Xichen Lin | Chief Scientific Officer | Acquired C | 5,939 | $0.00 | $0 | 5,939 | Direct |
| 01 Sep, 2026 | Xichen Lin | Chief Scientific Officer | Disposed S | 1,300 | $45.86 | $59.62K | 4,639 | Direct |
| 01 Sep, 2026 | Xichen Lin | Chief Scientific Officer | Disposed S | 4,539 | $47.20 | $214.25K | 100 | Direct |
| 01 Sep, 2026 | Xichen Lin | Chief Scientific Officer | Disposed S | 100 | $47.83 | $4.78K | 0 | Direct |
| 18 Aug, 2026 | Xichen Lin | Chief Scientific Officer | Acquired M | 11,817 | $0.34 | $4.02K | 240,777 | Direct |
| 18 Aug, 2026 | Xichen Lin | Chief Scientific Officer | Disposed C | 11,817 | $0.00 | $0 | 228,960 | Direct |
| 18 Aug, 2026 | Xichen Lin | Chief Scientific Officer | Disposed M | 11,817 | $0.00 | $0 | 142,898 | Direct |
| 18 Aug, 2026 | Xichen Lin | Chief Scientific Officer | Acquired C | 3,939 | $0.00 | $0 | 3,939 | Direct |
| 18 Aug, 2026 | Xichen Lin | Chief Scientific Officer | Disposed S | 3,020 | $53.13 | $160.46K | 919 | Direct |
| 18 Aug, 2026 | Xichen Lin | Chief Scientific Officer | Disposed S | 519 | $54.20 | $28.13K | 400 | Direct |
| 18 Aug, 2026 | Xichen Lin | Chief Scientific Officer | Disposed S | 400 | $55.05 | $22.02K | 0 | Direct |
| 06 Aug, 2026 | John Joseph Berrios | Chief Commercial Officer | Acquired A | 140,766 | $0.00 | $0 | 140,766 | Direct |
| 06 Aug, 2026 | John Joseph Berrios | Chief Commercial Officer | Acquired A | 174,612 | $0.00 | $0 | 174,612 | Direct |